Skip to main content

Advertisement

SpringerLink
Log in

Therapies for Hemorrhagic Transformation in Acute Ischemic Stroke

  • Critical Care Neurology (K Sheth, Section Editor)
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

Hemorrhagic transformation occurs in about 10–15% of patients with acute ischemic stroke. The treatment of hemorrhagic conversion is complex and includes blood pressure management, reversing coagulopathy, and managing its complications including increased intracranial pressure. Future research should be directed on identifying indications to treat and use of appropriate homeostatic regimens to effectively reverse the different anticoagulants and thrombolytic agents in an attempt to improve outcomes of patients with hemorrhagic transformation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Berger C, Fiorelli M, Steiner T, Schabitz W, Bozzao L, Bluhmki E, et al. Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic? Stroke. 2001;32:1330–5.

    Article  CAS  PubMed  Google Scholar 

  2. Group. TNIoNDaSr-PSS. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–7.

    Article  Google Scholar 

  3. Yaghi S, Elkind MS. Cryptogenic stroke: a diagnostic challenge. Neurol Clin Pract. 2014;4:386–93.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Khatri R, McKinney AM, Swenson B, Janardhan V. Blood–brain barrier, reperfusion injury, and hemorrhagic transformation in acute ischemic stroke. Neurology. 2012;79:S52–7.

    Article  PubMed  Google Scholar 

  5. Hamann GF, del Zoppo GJ, von Kummer R. Hemorrhagic transformation of cerebral infarction—possible mechanisms. Thromb Haemost. 1999;82 Suppl 1:92–4.

    PubMed  Google Scholar 

  6. Fujimura M, Gasche Y, Morita-Fujimura Y, Massengale J, Kawase M, Chan PH. Early appearance of activated matrix metalloproteinase-9 and blood–brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res. 1999;842:92–100.

    Article  CAS  PubMed  Google Scholar 

  7. Peters O, Back T, Lindauer U, Busch C, Megow D, Dreier J, et al. Increased formation of reactive oxygen species after permanent and reversible middle cerebral artery occlusion in the rat. J Cereb Blood Flow Metab. 1998;18:196–205.

    Article  CAS  PubMed  Google Scholar 

  8. del Zoppo GJ, von Kummer R, Hamann GF. Ischaemic damage of brain microvessels: inherent risks for thrombolytic treatment in stroke. J Neurol Neurosurg Psychiatry. 1998;65:1–9.

    Article  PubMed  Google Scholar 

  9. Lapchak PA, Chapman DF, Zivin JA. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke. 2000;31:3034–40.

    Article  CAS  PubMed  Google Scholar 

  10. Zhang J, Yang Y, Sun H, Xing Y. Hemorrhagic transformation after cerebral infarction: current concepts and challenges. Ann Transl Med. 2014;2:81.

    PubMed  PubMed Central  Google Scholar 

  11. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998;352:1245–51.

    Article  CAS  PubMed  Google Scholar 

  12. • von Kummer R, Broderick JP, Campbell BC, Demchuk A, Goyal M, Hill MD, et al. The Heidelberg Bleeding Classification: classification of bleeding events after ischemic stroke and reperfusion therapy. Stroke. 2015;46:2981–6. Take home message: The heidelberg bleeding classification may be used to classify bleeding events after ischemic stroke and reperfusion therapy.

    Article  Google Scholar 

  13. Fiorelli M, Bastianello S, Von Kummer R, Del Zoppo G, Larrue V, Lesaffre E, et al. Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. Stroke. 1999;30:2280–4.

    Article  CAS  PubMed  Google Scholar 

  14. Seet RC, Rabinstein AA. Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions. Cerebrovasc Dis. 2012;34:106–14.

    Article  PubMed  Google Scholar 

  15. Gumbinger C, Gruschka P, Bottinger M, Heerlein K, Barrows R, Hacke W, et al. Improved prediction of poor outcome after thrombolysis using conservative definitions of symptomatic hemorrhage. Stroke. 2012;43:240–2.

    Article  PubMed  Google Scholar 

  16. Trouillas P, von Kummer R. Classification and pathogenesis of cerebral hemorrhages after thrombolysis in ischemic stroke. Stroke. 2006;37:556–61.

    Article  PubMed  Google Scholar 

  17. Tan S, Wang D, Liu M, Zhang S, Wu B, Liu B. Frequency and predictors of spontaneous hemorrhagic transformation in ischemic stroke and its association with prognosis. J Neurol. 2014;261:905–12.

    Article  PubMed  Google Scholar 

  18. Lindley RI, Wardlaw JM, Sandercock PA, Rimdusid P, Lewis SC, Signorini DF, et al. Frequency and risk factors for spontaneous hemorrhagic transformation of cerebral infarction. J Stroke Cerebrovasc Dis. 2004;13:235–46.

    Article  PubMed  Google Scholar 

  19. • Yaghi S, Boehme AK, Dibu J, Leon Guerrero CR, Ali S, Martin-Schild S, et al. Treatment and outcome of thrombolysis-related hemorrhage: a multicenter retrospective study. JAMA Neurol. 2015;72:1451–7. Take home point: Hypofibfionegnemia is associated with hematoma expansion in patients with thrombolysis related hemorrhage.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Association of outcome with early stroke treatment. Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768–74.

    Article  Google Scholar 

  21. Lansberg MG, Bluhmki E, Thijs VN. Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. Stroke. 2009;40:2438–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Marsh EB, Llinas RH, Schneider AL, Hillis AE, Lawrence E, Dziedzic P, et al. Predicting hemorrhagic transformation of acute ischemic stroke: prospective validation of the HeRS Score. Medicine (Baltimore). 2016;95:e2430.

    Article  CAS  Google Scholar 

  23. Curtze S, Sibolt G, Melkas S, Mustanoja S, Haapaniemi E, Putaala J, et al. Symptomatic post-thrombolytic intracerebral hemorrhage is not related to the cause of stroke. Eur J Neurol. 2016.

  24. Cucchiara B, Kasner S, Tanne D, Levine S, Demchuk A, Messe S, et al. Validation assessment of risk scores to predict postthrombolysis intracerebral haemorrhage. Int J Stroke. 2011;6:109–11.

    Article  PubMed  Google Scholar 

  25. Mazya M, Egido JA, Ford GA, Lees KR, Mikulik R, Toni D, et al. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe implementation of treatments in stroke (SITS) symptomatic intracerebral hemorrhage risk score. Stroke. 2012;43:1524–31.

    Article  CAS  PubMed  Google Scholar 

  26. Lou M, Safdar A, Mehdiratta M, Kumar S, Schlaug G, Caplan L, et al. The HAT score: a simple grading scale for predicting hemorrhage after thrombolysis. Neurology. 2008;71:1417–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Strbian D, Meretoja A, Ahlhelm FJ, Pitkaniemi J, Lyrer P, Kaste M, et al. Predicting outcome of IV thrombolysis-treated ischemic stroke patients: the DRAGON score. Neurology. 2012;78:427–32.

    Article  CAS  PubMed  Google Scholar 

  28. Cucchiara B, Tanne D, Levine SR, Demchuk AM, Kasner S. A risk score to predict intracranial hemorrhage after recombinant tissue plasminogen activator for acute ischemic stroke. J Stroke Cerebrovasc Dis: Off J Nat Stroke Assoc. 2008;17:331–3.

    Article  Google Scholar 

  29. Saposnik G, Guzik AK, Reeves M, Ovbiagele B, Johnston SC. Stroke prognostication using age and NIH stroke scale: Span-100. Neurology. 2013;80:21–8.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Strbian D, Engelter S, Michel P, Meretoja A, Sekoranja L, Ahlhelm FJ, et al. Symptomatic intracranial hemorrhage after stroke thrombolysis: the SEDAN score. Ann Neurol. 2012;71:634–41.

    Article  PubMed  Google Scholar 

  31. Menon BK, Saver JL, Prabhakaran S, Reeves M, Liang L, Olson DM, et al. Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator. Stroke. 2012;43:2293–9.

    Article  CAS  PubMed  Google Scholar 

  32. Levi M, Eerenberg E, Kamphuisen PW. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost: JTH. 2011;9:1705–12.

    Article  CAS  PubMed  Google Scholar 

  33. Hemphill 3rd JC, Greenberg SM, Anderson CS, Becker K, Bendok BR, Cushman M, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46:2032–60.

    Article  PubMed  Google Scholar 

  34. Jauch EC, Saver JL, Adams Jr HP, Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44:870–947.

    Article  PubMed  Google Scholar 

  35. Frontera JA, Lewin 3rd JJ, Rabinstein AA, Aisiku IP, Alexandrov AW, Cook AM, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care. 2016;24:6–46.

    Article  CAS  PubMed  Google Scholar 

  36. Zhang Y, Reilly KH, Tong W, Xu T, Chen J, Bazzano LA, et al. Blood pressure and clinical outcome among patients with acute stroke in Inner Mongolia, China. J Hypertens. 2008;26:1446–52.

    Article  CAS  PubMed  Google Scholar 

  37. Rodriguez-Luna D, Pineiro S, Rubiera M, Ribo M, Coscojuela P, Pagola J, et al. Impact of blood pressure changes and course on hematoma growth in acute intracerebral hemorrhage. Eur J Neurol. 2013;20:1277–83.

    Article  CAS  PubMed  Google Scholar 

  38. Sakamoto Y, Koga M, Yamagami H, Okuda S, Okada Y, Kimura K, et al. Systolic blood pressure after intravenous antihypertensive treatment and clinical outcomes in hyperacute intracerebral hemorrhage: the Stroke Acute Management with Urgent Risk-Factor Assessment and Improvement-Intracerebral Hemorrhage Study. Stroke. 2013;44:1846–51.

    Article  CAS  PubMed  Google Scholar 

  39. Qureshi AI, Palesch YY, Barsan WG, Hanley DF, Hsu CY, Martin RL, et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med. 2016.

  40. McManus M, Liebeskind DS. Blood pressure in acute ischemic stroke. J Clin Neurol. 2016;12:137–46.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke. 2005;36:1588–93.

    Article  PubMed  Google Scholar 

  42. Fang M, Chang Y, Hylek EM, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004;141:745–52.

    Article  PubMed  Google Scholar 

  43. • Kuramatsu JB, Gerner ST, Schellinger PD, Glahn J, Endres M, Sobesky J, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA. 2015;313:824–36. Take home message: Very early reversal of coagulopathy and blood pressure control is associated with improved outcomes in patients with anticoagulation related intracerebral hemorrhage.

    Article  CAS  PubMed  Google Scholar 

  44. Huttner HB, Schellinger PD, Hartmann M, Kohrmann M, Juettler E, Wikner J, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin k, fresh frozen plasma, and prothrombin complex concentrates. Stroke. 2006;37:1465–70.

    Article  CAS  PubMed  Google Scholar 

  45. Ilyas C, Beyer GM, Dutton RP, Scalea TM, Hess JR. Recombinant factor VIIa for warfarin-associated intracranial bleeding. J Clin Anesth. 2008;20:276–9.

    Article  CAS  PubMed  Google Scholar 

  46. Brody DL, Aiyagari V, Shackleford AM, Diringer MN. Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocrit Care. 2005;2:263–7.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Sarode R, Milling Jr TJ, Refaai MA, Mangione A, Schneider A, Durn BL, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin k antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128:1234–43.

    CAS  PubMed  Google Scholar 

  48. Goldstein JN, Refaai MA, Milling Jr TJ, Lewis B, Goldberg-Alberts R, Hug BA, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin k antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet (London, England). 2015;385:2077–87.

    Article  CAS  Google Scholar 

  49. Ageno W, Crowther M, Steidl L, Ultori C, Mera V, Dentali F, et al. Low dose oral vitamin k to reverse acenocoumarol-induced coagulopathy: a randomized controlled trial. Thromb Haemost. 2002;88:48–51.

    CAS  PubMed  Google Scholar 

  50. Ageno W, Garcia D, Silingardi M, Galli M, Crowther M. A randomized trial comparing 1 mg of oral vitamin k with no treatment in the management of warfarin-associated coagulopathy in patients with mechanical heart valves. J Am Coll Cardiol. 2005;46:732–3.

    Article  CAS  PubMed  Google Scholar 

  51. Crowther MA, Ageno W, Schnurr T, Manfredi E, Kinnon K, Garcia D, et al. Oral vitamin k produces a normal INR within 24 hours of its administration in most patients discontinuing warfarin. Haematologica. 2005;90:137–9.

    CAS  PubMed  Google Scholar 

  52. Crowther MA, Wilson S. Vitamin k for the treatment of asymptomatic coagulopathy associated with oral anticoagulant therapy. J Thromb Thrombolysis. 2003;16:69–72.

    Article  CAS  PubMed  Google Scholar 

  53. Lubetsky A, Hoffman R, Zimlichman R, Eldor A, Zvi J, Kostenko V, et al. Efficacy and safety of a prothrombin complex concentrate (octaplex) for rapid reversal of oral anticoagulation. Thromb Res. 2004;113:371–8.

    Article  CAS  PubMed  Google Scholar 

  54. Pengo V, Banzato A, Garelli E, Zasso A, Biasiolo A. Reversal of excessive effect of regular anticoagulation: low oral dose of phytonadione (vitamin k1) compared with warfarin discontinuation. Blood Coagul Fibrinolysis : Int J Haemost Thromb. 1993;4:739–41.

    Article  CAS  Google Scholar 

  55. Raj G, Kumar R, McKinney WP. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. Arch Intern Med. 1999;159:2721–4.

    Article  CAS  PubMed  Google Scholar 

  56. Hung A, Singh S, Tait RC. A prospective randomized study to determine the optimal dose of intravenous vitamin k in reversal of over-warfarinization. Br J Haematol. 2000;109:537–9.

    Article  CAS  PubMed  Google Scholar 

  57. Butler JM, Groeger AW, Fletcher JS. Characterization of monochlorinated biphenyl products formed by Paul’s Scarlet Rose cells. Bull Environ Contam Toxicol. 1992;49:821–6.

    Article  CAS  PubMed  Google Scholar 

  58. Mi YN, Ping NN, Xiao X, Zhu YB, Liu J, Cao YX. The severe adverse reaction to vitamin K1 injection is anaphylactoid reaction but not anaphylaxis. PLoS One. 2014;9, e90199.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Nee R, Doppenschmidt D, Donovan DJ, Andrews TC. Intravenous versus subcutaneous vitamin K1 in reversing excessive oral anticoagulation. Am J Cardiol. 1999;83:286–8. a286-287.

    Article  CAS  PubMed  Google Scholar 

  60. Riegert-Johnson DL, Volcheck GW. The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review. Ann Allergy, Asthma Immunol: Off Publ Am Coll Allergy Asthma Immunol. 2002;89:400–6.

    Article  CAS  Google Scholar 

  61. Watson HG, Baglin T, Laidlaw SL, Makris M, Preston FE. A comparison of the efficacy and rate of response to oral and intravenous vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol. 2001;115:145–9.

    Article  CAS  PubMed  Google Scholar 

  62. Whitling AM, Bussey HI, Lyons RM. Comparing different routes and doses of phytonadione for reversing excessive anticoagulation. Arch Intern Med. 1998;158:2136–40.

    Article  CAS  PubMed  Google Scholar 

  63. Chapman SA, Irwin ED, Beal AL, Kulinski NM, Hutson KE, Thorson MA. Prothrombin complex concentrate versus standard therapies for INR reversal in trauma patients receiving warfarin. Ann Pharmacother. 2011;45:869–75.

    Article  CAS  PubMed  Google Scholar 

  64. Lee SB, Manno EM, Layton KF, Wijdicks EF. Progression of warfarin-associated intracerebral hemorrhage after INR normalization with FFP. Neurology. 2006;67:1272–4.

    Article  CAS  PubMed  Google Scholar 

  65. Woo CH, Patel N, Conell C, Rao VA, Faigeles BS, Patel MC, et al. Rapid warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. World Neurosurg. 2014;81:110–5.

    Article  PubMed  Google Scholar 

  66. Yasaka M, Sakata T, Minematsu K, Naritomi H. Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication. Thromb Res. 2002;108:25–30.

    Article  PubMed  Google Scholar 

  67. Dowlatshahi D, Butcher KS, Asdaghi N, Nahirniak S, Bernbaum ML, Giulivi A, et al. Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. Stroke. 2012;43:1812–7.

    Article  CAS  PubMed  Google Scholar 

  68. Frontera JA, Gordon E, Zach V, Jovine M, Uchino K, Hussain MS, et al. Reversal of coagulopathy using prothrombin complex concentrates is associated with improved outcome compared to fresh frozen plasma in warfarin-associated intracranial hemorrhage. Neurocrit Care. 2014;21:397–406.

    Article  CAS  PubMed  Google Scholar 

  69. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost: JTH. 2004;2:1700–8.

    Article  CAS  PubMed  Google Scholar 

  70. Butenas S, Brummel KE, Branda RF, Paradis SG, Mann KG. Mechanism of factor VIIa-dependent coagulation in hemophilia blood. Blood. 2002;99:923–30.

    Article  CAS  PubMed  Google Scholar 

  71. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008;358:2127–37.

    Article  CAS  PubMed  Google Scholar 

  72. O’Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006;295:293–8.

    Article  PubMed  Google Scholar 

  73. • Dibu JR, Weimer JM, Ahrens C, Manno E, Frontera JA. The role of FEIBA in reversing novel oral anticoagulants in intracerebral hemorrhage. Neurocrit Care. 2016;24:413–9. Take home message: Fieba may have a role in reversing intracerenral hemorrhage in the setting of oral novel anticoagulants.

    Article  CAS  PubMed  Google Scholar 

  74. Dinkelaar J, Molenaar PJ, Ninivaggi M, de Laat B, Brinkman HJ, Leyte A. In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for rivaroxaban. J Thromb Haemost: JTH. 2013;11:1111–8.

    Article  CAS  PubMed  Google Scholar 

  75. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573–9.

    Article  CAS  PubMed  Google Scholar 

  76. Herrmann R, Thom J, Wood A, Phillips M, Muhammad S, Baker R. Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban. Thromb Haemost. 2014;111:989–95.

    Article  CAS  PubMed  Google Scholar 

  77. Herzog E, Kaspereit F, Krege W, Doerr B, Mueller-Cohrs J, Pragst I, et al. Effective reversal of edoxaban-associated bleeding with four-factor prothrombin complex concentrate in a rabbit model of acute hemorrhage. Anesthesiology. 2015;122:387–98.

    Article  CAS  PubMed  Google Scholar 

  78. Korber MK, Langer E, Ziemer S, Perzborn E, Gericke C, Heymann C. Measurement and reversal of prophylactic and therapeutic peak levels of rivaroxaban: an in vitro study. Clin Appl Thromb/Hemost: Off J Int Acad Clin Appl Thromb/Hemost. 2014;20:735–40.

    Article  Google Scholar 

  79. Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost. 2012;108:217–24.

    Article  CAS  PubMed  Google Scholar 

  80. Perzborn E, Heitmeier S, Laux V, Buchmuller A. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. Thromb Res. 2014;133:671–81.

    Article  CAS  PubMed  Google Scholar 

  81. Zahir H, Brown KS, Vandell AG, Desai M, Maa JF, Dishy V, et al. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation. 2015;131:82–90.

    Article  CAS  PubMed  Google Scholar 

  82. • Glund S, Stangier J, Schmohl M, Gansser D, Norris S, van Ryn J, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet (London, England). 2015;386:680–90. Take home message: Idarucizumab is effective in reversing dabigatran induced coagulopathy.

    Article  CAS  Google Scholar 

  83. Kahn MRAR, Halperin JL. Risks to reversal of anticoagulation: the cardiology perspective. Nature. 2016;3:22–8.

    CAS  Google Scholar 

  84. Estes JW. The kinetics of heparin. Ann N Y Acad Sci. 1971;179:187–204.

    Article  CAS  PubMed  Google Scholar 

  85. Guffin AV, Dunbar RW, Kaplan JA, Bland Jr JW. Successful use of a reduced dose of protamine after cardiopulmonary bypass. Anesth Analg. 1976;55:110–3.

    Article  CAS  PubMed  Google Scholar 

  86. Jaques LB. A study of the toxicity of the protamine, salmine. Br J Pharmacol Chemother. 1949;4:135–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Parkin TW, Kvale WF. Neutralization of the anticoagulant effects of heparin with protamine (salmine). Am Heart J. 1949;37:333–42.

    Article  CAS  PubMed  Google Scholar 

  88. Harenberg J, Siegele M, Dempfle CE, Stehle G, Heene DL. Protamine neutralization of the release of tissue factor pathway inhibitor activity by heparins. Thromb Haemost. 1993;70:942–5.

    CAS  PubMed  Google Scholar 

  89. Holst J, Lindblad B, Bergqvist D, Hedner U, Nordfang O, Ostergaard P. The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man. Thromb Res. 1997;86:343–8.

    Article  CAS  PubMed  Google Scholar 

  90. Massonnet-Castel S, Pelissier E, Bara L, Terrier E, Abry B, Guibourt P, et al. Partial reversal of low molecular weight heparin (PK 10169) anti-XA activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation. Haemostasis. 1986;16:139–46.

    CAS  PubMed  Google Scholar 

  91. Matrat A, De Mazancourt P, Derex L, Nighoghossian N, Ffrench P, Rousson R, et al. Characterization of a severe hypofibrinogenemia induced by alteplase in two patients thrombolysed for stroke. Thromb Res. 2013;131:e45–48.

    Article  CAS  PubMed  Google Scholar 

  92. Tissue plasminogen activator for acute ischemic stroke. The national institute of neurological disorders and stroke rt-pa stroke study group. N Engl J Med. 1995;333:1581–1587.

  93. Matosevic B, Knoflach M, Werner P, Pechlaner R, Zangerle A, Ruecker M, et al. Fibrinogen degradation coagulopathy and bleeding complications after stroke thrombolysis. Neurology. 2013;80:1216–24.

    Article  CAS  PubMed  Google Scholar 

  94. French KF, White J, Hoesch RE. Treatment of intracerebral hemorrhage with tranexamic acid after thrombolysis with tissue plasminogen activator. Neurocrit Care. 2012;17:107–11.

    Article  CAS  PubMed  Google Scholar 

  95. Cast: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Cast (chinese acute stroke trial) collaborative group. Lancet. 1997;349:1641–1649.

  96. The international stroke trial (ist): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International stroke trial collaborative group. Lancet. 1997;349:1569–1581.

  97. Demchuk AM, Dowlatshahi D, Rodriguez-Luna D, Molina CA, Blas YS, Dzialowski I, et al. Prediction of haematoma growth and outcome in patients with intracerebral haemorrhage using the CT-angiography spot sign (predict): a prospective observational study. Lancet Neurol. 2012;11:307–14.

    Article  PubMed  Google Scholar 

  98. Sansing LH, Messe SR, Cucchiara BL, Cohen SN, Lyden PD, Kasner SE. Prior antiplatelet use does not affect hemorrhage growth or outcome after ICH. Neurology. 2009;72:1397–402.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke. 2007;38:423–30.

    Article  CAS  PubMed  Google Scholar 

  100. Saxena R, Lewis S, Berge E, Sandercock PA, Koudstaal PJ. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the international stroke trial. Stroke. 2001;32:2333–7.

    Article  CAS  PubMed  Google Scholar 

  101. Paciaroni M, Agnelli G, Falocci N, Caso V, Becattini C, Marcheselli S, et al. Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: effect of anticoagulation and its timing: The RAF study. Stroke. 2015;46:2175–82.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, The Warren Alpert Medical School of Brown University, 353 Eddy Street APC 530, Providence, RI, 02903, USA

    Joshua A. Stone MD, Shawna Cutting MD, Brian Silver MD, Bradford Thompson MD, Karen L. Furie MD & Shadi Yaghi MD

  2. Departments of Neurology, Columbia University Medical Center, New York, NY, USA

    Joshua Z. Willey MD

  3. Department of Neurology, Washington University School of Medicine, St. Louis, MI, USA

    Salah Keyrouz MD

  4. Department of Internal Medicine, Division of Hematology and Oncology, The Warren Alpert Medical School of Brown University, Providence, RI, USA

    James Butera MD

  5. Department of Diagnostic Imaging, The Warren Alpert Medical School of Brown University, Providence, RI, USA

    Ryan A. McTaggart MD

  6. Department of Neurosurgery, The Warren Alpert Medical School of Brown University, Providence, RI, USA

    Bradford Thompson MD

Authors
  1. Joshua A. Stone MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joshua Z. Willey MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Salah Keyrouz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. James Butera MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ryan A. McTaggart MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shawna Cutting MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Brian Silver MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Bradford Thompson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Karen L. Furie MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Shadi Yaghi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shadi Yaghi MD.

Ethics declarations

Conflict of Interest

Joshua A. Stone, Salah Keyrouz, James Butera, Ryan A. McTaggart, Shawna Cutting, Brian Silver, Bradford Thompson, and Karen L. Furie declare that they have no conflict of interest.

Joshua Z. Willey received funding from the NIH (NINDS K23NS 073104).

Shadi Yaghi received funding from the New York Stroke Trials Network of Columbia and Cornell (NYCCSTN, NINDS U10NS086728).

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Critical Care Neurology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stone, J.A., Willey, J.Z., Keyrouz, S. et al. Therapies for Hemorrhagic Transformation in Acute Ischemic Stroke. Curr Treat Options Neurol 19, 1 (2017). https://doi.org/10.1007/s11940-017-0438-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11940-017-0438-5

Keywords

Search

Navigation